David Sumerauer
Impact in
- Genetics top 0.2%
- Glioma Diagnosis and Treatment
- BRCA gene mutations in cancer
- Genomic variations and chromosomal abnormalities
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
- Genetics 48
- Glioma Diagnosis and Treatment 48
- BRCA gene mutations in cancer 3
- Blood disorders and treatments 2
-
- Sarcoma Diagnosis and Treatment 9
- Co-authors
- Roman Kodet (16 shared papers)Zdeněk Sedláček (4 shared papers)Lenka Krsková (16 shared papers)Marie Trková (2 shared papers)Edita Kabíčková (4 shared papers)Otakar Bělohlávek (2 shared papers)Marcela Mrhalová (4 shared papers)Martin Kynčl (17 shared papers)
In The Last Decade
David Sumerauer
71 papers receiving 3.8k citations
David Sumerauer's Hit Papers
Peers
Comparison fields: 5 of 67
- Genetics 2.1k
- Cancer Research 303
- Pathology and Forensic Medicine 231
- Molecular Biology 848
- Oncology 225
Countries citing papers authored by David Sumerauer
This map shows the geographic impact of David Sumerauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sumerauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sumerauer more than expected).
Fields of papers citing papers by David Sumerauer
This network shows the impact of papers produced by David Sumerauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sumerauer. The network helps show where David Sumerauer may publish in the future.
Co-authors
The 25 scholars most cited alongside David Sumerauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma Hit paper breakdown → | 2014 | 520 |
| 2 | 2016 | 442 | |
| 3 | 2018 | 284 | |
| 4 | 2017 | 270 | |
| 5 | 2019 | 266 | |
| 6 | 2016 | 191 | |
| 7 | 2020 | 130 | |
| 8 | 2018 | 117 | |
| 9 | 2016 | 115 | |
| 10 | 2020 | 109 | |
| 11 | 2022 | 105 | |
| 12 | 2019 | 104 | |
| 13 | 2019 | 99 | |
| 14 | 2021 | 75 | |
| 15 | 2005 | 70 | |
| 16 | 2006 | 67 | |
| 17 | 2016 | 63 | |
| 18 | 2021 | 62 | |
| 19 | 2017 | 50 | |
| 20 | 2017 | 49 |
About David Sumerauer
David Sumerauer is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Oncology and Molecular Biology, having authored 77 papers that have together received 3.8k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (48 papers), Chromatin Remodeling and Cancer (10 papers), Sarcoma Diagnosis and Treatment (9 papers), Genetic factors in colorectal cancer (4 papers), BRCA gene mutations in cancer (3 papers), Blood disorders and treatments (2 papers), Cancer-related Molecular Pathways (2 papers) and Lymphoma Diagnosis and Treatment (2 papers). The work is most often cited by research in Genetics (2.1k citations), Cancer Research (303 citations), Pathology and Forensic Medicine (231 citations), Molecular Biology (848 citations) and Oncology (225 citations). David Sumerauer has collaborated with scholars based in Czechia, Germany and Canada. Frequent co-authors include Roman Kodet, Zdeněk Sedláček, Lenka Krsková, Marie Trková, Edita Kabíčková, Otakar Bělohlávek, Marcela Mrhalová, Martin Kynčl, Petr Libý and Michal Zápotocký. Their work appears in journals such as Neuro-Oncology, Acta Neuropathologica, Child s Nervous System, Acta Neurochirurgica and Journal of Neuro-Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.